Neurological complications of chemotherapy in lymphoma and leukemia patients

Lymphoma and Leukemia of the Nervous System

Volumn , Issue , 2012, Pages 357-381

  Quant, Eudocia C ^a   Fisher, David C ^b   Wen, Patrick Y ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84955055524     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/9781441976680_22     Document Type: Chapter

References (181)

1. Onciu M (2009) Acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23: 655-674
2. Shipley JL, Butera JN (2009) Acute myelogenous leukemia. Exp Hematol 37: 649-658
3. Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8:581-592
4. Hsi ED (2009) The leukemias of mature lymphocytes. Hematol Oncol Clin North Am 23:843-871
5. Milojkovic D, Apperley J (2008) State-of-the-art in the treatment of chronic myeloid leukaemia. Curr Opin Oncol 20:112-121
6. Evens AM, Hutchings M, Diehl V (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 5:543-556
7. Sweetenham JW (2008) Highly aggressive lymphomas in adults. Hematol Oncol Clin North Am 22:965-978.
8. Thomas X, Le QH (2008) Central nervous system involvement in adult acute lymphoblastic leukemia. Hematology 13:293-302
9. Liesveld JL, Lichtman MA (2006) Acute myelogenous leukemia. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT (eds) Williams hematology, 7th edn. McGraw-Hill Medical, New York, NY, pp 1183-1236
10. Pfeifer H, Wassmann BJ, Hofmann WK (2003) Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 9:4674-4681
11. Rytting ME, Wierda WG (2004) Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 45:1623-1626
12. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804-815
13. Denier C, Tertian G, Ribrag V et al (2009) Multifocal deficits due to leukemic meningoradi-culitis in chronic lymphocytic leukemia. J Neurol Sci 277:130-132
14. Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281-1288
15. Batchelor T, Carson K, O'Neil A et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21(6):1044-1049
16. Ferreri AJ, Crochhiolo R, Assanelli A et al (2008) High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 49:2042-2047
17. McAllister LD, Doolittle ND, Guastadisegni PE et al (2000) Cognitive outcomes and longterm follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51-60, 60-61 discussion
18. Shah GD, Yahalom J, Correa DD et al (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730-4735
19. Glantz MJ, Cole BF, Recht L et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561-1567
20. Tetef ML, Margolin KA, Doroshow JH et al (2000) Pharmacokinetics and toxicity of highdose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46:19-26
21. Vassal G, Valteau D, Bonnay M et al (1990) Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non-Hodgkin’s lymphoma. Pediatr Hematol Oncol 7:71-77
22. Omuro AM, Ben-Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595-1600
23. Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16(3):859-863
24. Abrey LE, Yahalom J, DeAngelis LM et al (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18(17):3144-3150
25. Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570-4574
26. Seam P, Janik JE, DeAngelis LM et al (2009) Role of chemotherapy in Hodgkin’s lymphoma. Cancer J 15:150-154
27. Brice P (2008) Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 141: 3-13
28. Quddus F, Armitage JO (2009) Salvage therapy for Hodgkin’s lymphoma. Cancer J 15: 161-163
29. Gribben JG (2007) How I treat indolent lymphoma. Blood 109:4617-4626
30. Feuerlein K, Zucca E, Ghielmini M et al (2009) First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma 50:325-334
31. Michallet AS, Coiffier B (2009) Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 23:11-23
32. Friedberg JW, Fisher RI (2008) Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 22:941-952.
33. Wrench D, Gribben JG (2008) Stem cell transplantation for non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am 22:1051-1079.
34. Lim HY, Thiel E, Glantz MJ (2008) To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin’s lymphoma. Curr Opin Oncol 20:495-501
35. Mead GM, Sydes MR, Walewski J et al (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom lymphoma group LY06 study. Ann Oncol 13:1264-1274
36. Magrath I, Adde M, Shad A et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934
37. Lippens RJ, Winograd B (1988) Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol 5:115-124
38. Geiser CF, Bishop Y, Jaffe N et al (1975) Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 45:189-195
39. Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394-3402
40. Phillips PC (1991) Methotrexate toxicity. In: Rottenberg DA (ed) Neurological complications of cancer treatment. Butterworth-heinemann, Boston, MA, pp 115-134
41. DeAngelis LM, Posner JB (2009) Side effects of chemotherapy: Neurologic complications of cancer. Oxford University Press, New York, NY, pp 447-510
42. Boogerd W, vd Sande JJ, Moffie D et al (1988) Acute fever and delayed leukoencephalopa-thy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51(10):1277-1283
43. Bates S, McKeever P, Masur H et al (1985) Myelopathy following intrathecal chemotherapy in a patient with extensive Burkitt’s lymphoma and altered immune status. Am J Med 78: 697-702
44. McLean DR, Clink HM, Ernst P et al (1994) Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes. Cancer 73:3037-3040
45. Gagliano RG, Costanzi JJ (1976) Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 37:1663-1668
46. Clark AW, Cohen SR, Nissenblatt MJ et al (1982) Paraplegia following intrathecal chemotherapy: neuropathologic findings and elevation of myelin basic protein. Cancer 50:42-47
47. Counsel P, Khangure M (2007) Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Clin Radiol 62:172-176
48. Lemann W, Wiley RG, Posner JB (1988) Leukoencephalopathy complicating intraventricular catheters: clinical, radiographic and pathologic study of 10 cases. J Neurooncol 6: 67-74
49. Baehring JM, Fulbright RK (2008) Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 79:535-539
50. Riva D, Giorgi C, Nichellli F et al (2002) Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 59:48-53
51. Dicuonzo F, Salvati A, Palma M et al (2009) Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol 24:1013-1018
52. Winick NJ, Bowman WP, Kamen BA et al (1992) Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 84:252-256
53. Yim YS, Mahoney DH Jr, Oshman DG (1991) Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 67:2058-2061
54. Anderson SC, Baquies GD, Jackson A et al (2002) Ventral polyradiculopathy with pediatric acute lymphocytic leukemia. Muscle Nerve 25(1):106-110
55. Koh S, Nelson MD Jr, Kovanlikaya A et al (1999) Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 21:576-578
56. Pascual AM, Coret F, Casanova B et al (2008) Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate. J Neurol Sci 267(1-2):158-161
57. Bernstein ML, Sobel DB, Wimmer RS (1982) Noncardiogenic pulmonary edema following injection of methotrexate into the cerebrospinal fluid. Cancer 50:866-868
58. Shore T, Barnett MJ, Phillips GL (1990) Sudden neurologic death after intrathecal methotrexate. Med Pediatr Oncol 18:159-161
59. Paleologos N (1998) Complications of chemotherapy. In: Biller J (ed) Iatrogenic neurology. Butterworth-heinemann, Boston, MA, pp 439-460
60. Dietrich J, Wen PY (2008) Neurologic complications of chemotherapy. In: Schiff D, Kesari S, Wen PY (eds) Cancer neurology in clinical practice, Humana Press, Totowa, NJ, pp 287-326
61. Ettinger LJ (1982) Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 50:444-450
62. Finkelstein Y, Zevin S, Heyol J et al (2004) Emergency treatment of life-threatening intrathecal methotrexate overdose. Neurotoxicology 25:407-410
63. Spiegel RJ, Cooper PR, Blun RH et al (1984) Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 311:386-388
64. Widemann BC, Balis FM, Shalabi A et al (2004) Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 96(20):1557-1559
65. Wernick R, Smith DL (1989) Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 32:770-775
66. Schmiegelow K (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146:489-503
67. Rubnitz JE, Relling MV, Harrison PL et al (1998) Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 12:1176-1181
68. Sanchez-Carpintero R, Narbona J, Lopez de Mesa R et al (2001) Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 24:145-148
69. Erbetta A, Salmaggi A, Sghirlanzoni A et al (2008) Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments. Neurol Sci 29:131-137
70. Martino RL, Benson AB, 3rd, Merritt JA et al (1984) Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma. Cancer 54:2003-2005
71. Walker RW, Allen JC, Rosen G et al (1986) Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 4:1845-1850
72. Inaba H, Khan RB, Laninghan FH et al (2008) Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 19:178-184
73. Borgna-Pignatti C, Battisti L, Marradi P et al (1992) Transient neurologic disturbances in a child treated with moderate-dose methotrexate. Br J Haematol 81:448
74. Phillips PC, Dhawan Y, Strother SC et al (1987) Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol 21:59-63
75. Millot F, Dhondt JL, Hayte JM et al (1992) Impairment of cerebral biogenic amine synthesis in a patient receiving high-dose methotrexate. Am J Pediatr Hematol Oncol 14:276-278
76. Chabner BA, Allegra CJ, Curt GA et al (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907-912
77. Pizzo PA, Poplack DG, Blyer WA et al (1979) Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1:127-140
78. Rubinstein LJ, Herman MM, Long TF et al (1975) Disseminated necrotizing leukoen-cephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 35:291-305
79. Shuper A, Stark B, Kornreich L et al (2000) Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 15:573-580
80. Lai R, Abrey LE, Rosenblum MK et al (2004) Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62:451-456
81. Ochs J, Mulhern R, Fairclough D et al (1991) Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 9: 145-151
82. Oka M, Terae S, Kobayashi R et al (2003) MRI in methotrexate-related leukoencephalopa-thy: disseminated necrotising leukoencephalopathy in comparison with mild leukoen-cephalopathy. Neuroradiology 45:493-497
83. Price RA, Birdwell DA (1978) The central nervous system in childhood leukemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 42:717-728
84. Davidson A, Payne G, Leach MO et al (2000) Proton magnetic resonance spectroscopy ((1)H-MRS) of the brain following high-dose methotrexate treatment for childhood cancer. Med Pediatr Oncol 35:28-34
85. Casey EB, Jellife AM, Le Quesne PM et al (1973) Vincristine neuropathy. Clinical and electrophysiological observations. Brain 96:69-86
86. Legha SS (1986) Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1:421-427
87. McLeod JG, Penny R (1969) Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 32:297-304
88. Weintraub M, Adde MA, Venzon DJ et al (1996) Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 14:935-940
89. Sandler SG, Tobin W, Henderson ES et al (1969) Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 19:367-374
90. Nishikawa T, Kawakami K, Kumamoto T et al (2008) Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30:519-521
91. Naumann R, Moham J, Reuner U et al (2001) Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol 115:323-325
92. Munier F, Perentes E, Herbort CP et al (1992) Selective loss of optic nerve beta-tubulin in vincristine-induced blindness. Am J Med 93:232-234
93. Gaidys WG, Dickerman JD, Walters CL et al (1983) Intrathecal vincristine. Report of a fatal case despite CNS washout. Cancer 52:799-801
94. Robertson GL, Bhoopalam N, Zelkowitz LJ (1973) Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 132:717-720
95. Hurwitz RL, Mahoney DH Jr, Armstrong DL et al (1988) Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 16: 216-219
96. Byrd RL, Rohrbaugh TM, Raney RB Jr et al (1981) Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 47:37-40
97. Boranic M, Raci F (1979) A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine 31:124-125
98. Fazeny B, Zifko U, Meryn S et al (1996) Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 39:150-156
99. Herzig RH, Hines JD, Herzig GP et al (1987) Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 5(6):927-932
100. Hwang TL, Yung WK, Estey EH et al (1985) Central nervous system toxicity with high-dose Ara-C. Neurology 35:1475-1479
101. Winkelman MD, Hines JD (1983) Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 14:520-527
102. Gottlieb D, Bradstock K, Koutts J et al (1987) The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 60:1439-1441
103. Smith GA, Damon LE, Rugo HS et al (1997) High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 15:833-839
104. Johnson NT, Crawford SW, Sargur M (1987) Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation. Bone Marrow Transplant 2:203-207
105. Ritch PS, Hansen RM, Heuer DK (1983) Ocular toxicity from high-dose cytosine arabi-noside. Cancer 51:430-432
106. Baker WJ, Royer GL Jr, Weirs RB (1991) Cytarabine and neurologic toxicity. J Clin Oncol 9:679-693
107. Luque FA, Selhorst JB, Petruska P (1987) Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 2:219-222
108. Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110-3116
109. Dunton SF, Nitschke R, Spruce WE et al (1986) Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A pediatric oncology group study. Cancer 57:1083-1088
110. Resar LM, Phillips PC, Kastan MB et al (1993) Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 71:117-123
111. Eden OB, Goldie W, Wood T et al (1978) Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia. Cancer 42:53-58
112. Fort JA, Smith LD (1999) Pseudotumor cerebri secondary to intermediate-dose cytarabine HCl. Ann Pharmacother 33:576-578
113. Kleinschmidt-DeMasters BK, Yeh M (1992) “Locked-in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 70: 2504-2507
114. Watkin SW, Husband DJ, Green JA et al (1989) Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 25:1303-1310
115. Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80:556-566
116. Buesa JM, Garcia-Teijido P, Losa R et al (2003) Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res 9:4636-4637
117. Pelgrims J, De Vos F, Van den Brande J et al (2000) Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82:291-294
118. Gieron MA et al (1988) Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J Neurooncol 6(1):29-30
119. Shuper A, Stein J, Goshen J et al (2000) Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication. J Child Neurol 15:481-483
120. Schachter S, Freeman R (1982) Transient ischemic attack and adriamycin cardiomyopathy. Neurology 32:1380-1381
121. Arico M, Nespoli L, Porta F et al (1990) Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. Med Pediatr Oncol 18:261-263
122. Vandenberg SA, Kulig K, Spoerke DG et al (1988) Chlorambucil overdose: accidental ingestion of an antineoplastic drug. J Emerg Med 6:495-498
123. Wyllie AR, Bayliff CD, Kovacs MJ (1997) Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 31:171-174
124. Salloum E, Khan KK, Cooper DL (1997) Chlorambucil-induced seizures. Cancer 79: 1009-1013
125. Burns LJ (1992) Ocular toxicities of chemotherapy. Semin Oncol 19:492-500
126. Chabner BA, Longo DL (1996) Cancer chemotherapy and biotherapy: principles and practice, Lippincott-Raven, Philadelphia, PA
127. Kende G, Sirkin SR, Thomas PR et al (1979) Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer 44:69-71
128. Tashima CK (1975) Immediate cerebral symptoms during rapid intravenous administration of cyclophosphamide (NSC-26271). Cancer Chemother Rep 59:441-442
129. Leff RS, Thompson JM, Daly MB et al (1988) Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 62:32-35
130. Chamberlain MC, Tsao-wei DD, Groshen S (2006) Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 106:2021-2027
131. Cheson BD, Vena DA, Foss FM et al (1994) Neurotoxicity of purine analogs: a review. J Clin Oncol 12:2216-2228
132. Cohen RB, Abdsallah JM, Gray JR et al (1993) Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 118:114-116
133. Spriggs DR, Stopa E, Mayer RJ et al (1986) Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 46:5953-5958
134. Hammack JE, Cascino TL (1998) Chemotherapy and other common drug-induced toxicities of the central nervous system in patients with cancer. In: Vecht CJ (ed) Handbook of clinical neurology. Elsevier Science, Amsterdam, pp 481-514
135. Chun HG, Leyland-Jones BR, Caryk SM et al (1986) Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225-1228
136. Warreil RP Jr, Berman E (1986) Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74-79
137. Cid J, Revilla M, Cervera A et al (2000) Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 79:392-395
138. Kiewe P, Seyfert S, Korper S et al (2003) Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 44:1815-1818
139. Rodriguez L, Ribera JM, Batlle M et al (2002) Progressive multifocal leukoencephalopa-thy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine. Haematologica 87:ECR26
140. Saumoy M, Castells G, Escoda L et al (2002) Progressive multifocal leukoencephalopa-thy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 43: 433-436
141. Sullivan KM, Storb R, Shulman HM et al (1982) Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med 97:182-189
142. Burger PC, Kamenar E, Schold SC et al (1981) Encephalomyelopathy following high-dose BCNU therapy. Cancer 48:1318-1327
143. Weiss HD, Walker MD, Wiernik PH (1974) Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med 291:127-133
144. Postma TJ, van Groenigen CJ, Witjes RJ et al (1998) Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 38(1):69-75
145. Spivack SD (1974) Drugs 5 years later: procarbazine. Ann Intern Med 81:795-800
146. Gutin PH, Levi JA, Wiernik PH et al (1977) Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 61:885-887
147. Drappatz J, Schiff D, Kesaru S et al (2007) Medical management of brain tumor patients. Neurol Clin 25:1035-1071
148. DeAngelis LM, Posner JB (2009b) Supportive care and its complications: Neurologic complications of cancer. Oxford University Press, New York, NY, pp 95-140
149. Batchelor TT, Taylor LP, Thaler HT et al (1997) Steroid myopathy in cancer patients. Neurology 48:1234-1238
150. Dropcho EJ, Soong SJ (1991) Steroid-induced weakness in patients with primary brain tumors. Neurology 41:1235-1239
151. Stiefel FC, Breitbart WS, Holland JC (1989) Corticosteroids in cancer: neuropsychiatrie complications. Cancer Invest 7:479-491
152. Lewis DA, Smith RE (1983) Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 5:319-332
153. Baethge BA, Lidsky MD (1986) Intractable hiccups associated with high-dose intravenous methylprednisolone therapy. Ann Intern Med 104:58-59
154. Haddad SF, Hitchon PW, Godersky JC (1991) Idiopathic and glucocorticoid-induced spinal epidural lipomatosis. J Neurosurg 74:38-42
155. Caraceni A, Gangeri L, Martini C et al (1998) Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 83:482-489
156. Meyers CA, Obbens EA, Scheibel RS et al (1991) Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68:88-92
157. Meyers CA, Scheibel RS, Forman AD (1991) Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41:672-676
158. Rohatiner AZ, Prior PF, Burton AC et al (1983) Central nervous system toxicity of interferon. Br J Cancer 47:419-422
159. Spiegel RJ (1987) The alpha interferons: clinical overview. Semin Oncol 14:1-12
160. Hensley ML, Peterson B, Silver RT et al (2000) Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 18:1301-1308
161. Smedley H, Katrak M, Sikora K et al (1983) Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) 286:262-264
162. Suter CC, Westmoreland BF, Shabrough FW et al (1984) Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 59:847-850
163. Hejny C, Sternberg P, Lawson DH et al (2001) Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 131:782-787
164. Vesikari T, Nuutila A, Cantell K (1988) Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 77:619-622
165. Raison CL, Demetrashvili M, Capuron L et al (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19:105-123
166. Michallet M, Maloisel F, Delain M et al (2004) Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 18:309-315
167. Adamson PC, Reaman G, Finklestein JZ et al (1997) Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol 15:3330-3337
168. Tallman MS, Andersen JW, Schiffer CA et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028
169. Maloney DG, Press OW (1998) Newer treatments for non-Hodgkin’s lymphoma: monoclonal antibodies. Oncology (Williston Park) 12:63-76
170. Foran JM, Rohatiner AZ, Cunninghan D et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324
171. Kaminski MS, Estes J, Zasadny KR et al (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266
172. Vose JM, Wahl RL, Saleh M et al (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 18:1316-1323
173. Dillman RO, Hendrix CS (2003) Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 1:38-48
174. Morschhauser F, Radford J, Van Hoof A et al (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164
175. Apisarnthanarax N (2002) Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 3:193-215
176. Olsen E, Duvic M, Frankal A et al (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388
177. Deininger MW, O'Brien SG, Ford JM et al (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21:1637-1647
178. Kantaijian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652
179. Penel N, Blay JY, Adenis A et al (2008) Imatinib as a possible cause of severe rhabdomyol-ysis. N Engl J Med 358:2746-2747
180. Song KW, Rifkind J, Al-Beirouti B et al (2004) Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma 45:1633-1636
181. Schiff D, Wen PY, van den Bent MJ et al (2009) Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 6:596-603